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Abstract
Background: In β-thalassemia, profound anemia and severe hemosiderosis cause functional and physiological 
abnormalities in various organ systems. In recent years, there have been few published studies mainly in adult 
demonstrating renal involvement in β-thalassemia. This prospective study was aimed to investigate renal involvement 
in pediatric patients with transfusion dependant beta-thalassemia major (TD-βTM), using both conventional and early 
markers of glomerular and tubular dysfunctions, and to correlate findings to oxidative stress and iron chelation therapy.
Methods: Sixty-nine TD-βTM patients (aged 1-16 years) and 15 healthy controls (aged 3-14 years) were enrolled in this 
study. Based on receiving chelation therapy (deferoxamine, DFO), patients were divided into two groups: group [I] with 
chelation (n = 34) and group [II] without chelation (n = 35). Levels of creatinine (Cr), calcium (Ca), inorganic phosphorus 
(PO4), uric acid (UA) and albumin were measured by spectrophotometer. Serum (S) levels of cystatin-C (SCysC) and total 
antioxidant capacity (STAC) and urinary (U) levels of β2-microglobulin (Uβ2MG) were measured by immunosorbent assay 
(ELISA). Urinary N-acetyl-beta-D-glucosaminidase (UNAG) activity and malondialdehyde (UMDA) were measured by 
chemical methods. Estimated glomerular filtration rate (eGFR) was determined from serum creatinine.
Results: In patient with and without chelation, glomerular [elevated SCysC, SCr, Ualbumin/Cr and diminished eGFR]; and 
tubular dysfunctions [elevated SUA, SPO4, UNAG/Cr, Uβ2MG/Cr] and oxidative stress marker disturbances [diminished STAC 
and elevated UMDA/Cr] were reported than controls. In patients with chelation, SCysC was significantly higher while, STAC 
was significantly lower than those without chelation. In all patients, SCysC showed significant positive correlation with 
SCr and negative correlation with eGFR; STAC showed significant positive correlation with eGFR and negative correlation 
with SCysC, SCr, UNAG/Cr; UMDA/Cr showed significant positive correlation with Ualbumin/Cr, Uβ2MG/Cr, UNAG/Cr.
Conclusions: Our data confirm high frequency of glomerular and tubular dysfunctions in TD-βTM pediatric patients 
which could be attributed to oxidative stress and DFO therapy.
Background
β-thalassaemia major (βTM), is a type of chronic, inher-
ited, microcytic anemia that is characterized by impaired
biosynthesis of the β-globin leading to accumulation of
unpaired α-globin chain. Although the prognosis for
patients with thalassaemia has greatly improved in recent
decades with the use of modern newborn screening,
blood transfusions and iron chelation therapy; multi-
organ dysfunctions is still common. Patients with thalas-
semia are known to have severe cardiopulmonary, reticu-
loendothelial, and other major systems dysfunction, but
renal involvement has received little attention. Increased
renal plasma flow and failure of urine concentration abil-
ity had been reported in adult subjects with β-thalas-
semia since 1975 [1]. Also, renal tubular acidosis had also
been reported in patients with thalassemia [2]. In recent
years, there have been few published studies demonstrat-
ing proteinuria, aminoaciduria, low urine osmolarity, and
excess secretion of the proximal tubule damage markers,
such as N-acetyl-beta-D-glucosaminidase (NAG) activity
in such patients [3-5]. Shortened red blood cells (RBCs)
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life span, rapid iron turnover, and tissue deposition of
excess iron are major factors responsible for functional
and physiological abnormalities found in various forms of
thalassemia. On the other hand, deferoxamine (DFO)
therapy has been proved to be nephrotoxic and induce
dose-dependent proximal tubular dysfunction by an
unknown mechanism [6,7]. Thus, the necessity of moni-
toring renal damage in thalassemic patients receiving
DFO therapy has been well-recognized.
Reports investigating renal dysfunction in thalassemic
have been limited in number, mainly studying adult
patients. Additionally, most of them have not assessed,
early markers of glomerular and tubular functions, such
as serum (S) cystatin-C (SCysC), urinary (U) β2-microglob-
ulin (Uβ2MG) and UNAG. Early identification of patients at
high risk of developing renal damage is of great impor-
tance as it may allow specific measures to be undertaken
that will delay the progression of renal injury and thus
reduce the incidence of renal impairment. Therefore, the
aim of the present study was to: 1) investigate the pres-
ence of glomerular and/or tubular dysfunctions in chil-
dren and adolescent with transfusion dependant (TD)
βTM, without any overt renal diseases, using both con-
ventional and early markers of glomerular and tubular
dysfunctions. 2) To correlate the findings to oxidative
stress markers and iron chelation therapy with DFO.
Patients and Methods
Sixty-nine follow up pediatric patients with TD-βTM
recruited to Hematology Clinic of Pediatric Hospital, Fac-
ulty of Medicine, Assiut University, Assiut, Egypt, were
randomly selected to participate in this prospective study
during the period from January 2008 to June 2009. The
diagnosis of βTM was based on standard criteria [6]. The
study was approved by the Ethical Committee of Faculty
of Medicine, Assiut University and informed consent was
obtained in every case from their legal guardians.
All patients were in a stable phase of their disease with
regular erythrocyte transfusion/1-2 months (TD) since
early childhood to maintain pretransfusional hemoglobin
levels above 9 g/dL. Patients were divided into 2 groups,
group I (n = 34) on regular iron DFO chelation therapy
(20-60 mg/kg/day usually administered subcutaneously
via a battery-operated portable pump over a period of 8-
12 hours overnight, for 5-7 nights per week) to maintain
serum ferritin level below 1000 ng/mL and group II (n =
35) without chelation therapy due to failure of treatment
as a result of hypersensitivity to DFO or non-compliance.
Failure of treatment was defined as an increase of serum
ferritin levels >1000 ng/mL with respect to the previous
values, confirmed by two determinations. Those patients
who were unable to afford its prohibitive cost or unwill-
ing to receive daily regularly rigorous subcutaneous infu-
sions of DFO were considered as non-compliant.
Demographic and clinical conditions included age, sex,
weight, height, age of puberty, disease duration, number
of blood transfusions/year, history of splenectomy, post-
splenectomy duration, chelation therapy were obtained
by interview and chart review. Patients were splenecto-
mized when the transfusion requirements of packed red
blood cells increased to 180 mL/kg/year, presence of
hypersplenism signs such as leucopenia or thrombocy-
topenia, or presence of large spleen. Fifteen age-, sex-,
body mass index (BMI)-matching healthy volunteer sub-
jects attending the child health promotion clinic of hospi-
tal were recruited in this study as controls. Clinical
examination was implemented for all participants.
Children and adolescence with clinical or laboratory
evidence of renal pathology, systemic illness (cardiac, thy-
roid, hepatic diseases, diabetes mellitus or sepsis, etc.) or
the need of renal replacement or diuretic therapy or his-
tory of intake of trimethoprim, corticosteroids or cepha-
losporin in the past 7 days, were excluded from this study.
P a t i e n t s  w e r e  i n s t r u c t e d  t o  f a s t  o v e r n i g h t  b e f o r e
attending the clinic in the morning and advised to abstain
from taking any medications (including chelation), vita-
min or mineral supplements for the previous 24 hours.
Just before blood transfusion, fasting venous blood and
fresh second-morning midstream urine samples were
collected from all the participants (between 7-8 a.m.) for
hematological and biochemical analysis. Serum and uri-
nary samples were recovered and immediately aliquot
and frozen at -70°C till use. Glomerular functions were
assessed by measuring serum and urinary creatinine
(Creatinine-Jaffe enzymatic assay) and urinary albumin
by colorimetrically (Egypt Company for Biotechnology,
Cairo, Egypt). Patients were considered to have preclini-
cal glomerular damage if urinary albumin/creatinine
ratio was 2.5-30 mg/mmol.Cr and to have glomerular
proteinuria if urinary albumin/creatinine ratio was >30
mg/mmol.Cr [8]. SCysC l e v e l s  w e r e  m e a s u r e d  b y  q u a n -
tikine human cystatin-C immunosorbent assay (ELISA)
kit [Cat. No. DSCTC0; R&D systems, Inc., Minneapolis,
MN, USA] [9]. Estimated glomerular filtration rate
(eGFR) was calculated using Schwartz formula for chil-
dren [10]: eGFR (ml/min/1.73 m2) = height (cm) × con-
stant/serum creatinine (mg/dL), where height was
expressed in "cm" and constants was 0.44 (for children < 2
years) and 0.55 (for children ≥2 years). Renal dysfunction
was defined as eGFR < 90 mL/min/1.73 m2 [11]. Tubular
functions were assessed by measuring serum and urinary
calcium (Ca), inorganic phosphorus (PO4) and uric acid
(UA) by colorimetric method (Egypt company for bio-
technology, Cairo, Egypt); β2MG was measured by an
ELISA kit [Cat. No. ORG5BM; Orgente Dignostika,
GmbH, Mainz, Germany] [12] and UNAG by chemical
method [13]. In order to minimize urine flow rate on uri-Hamed and ElMelegy Italian Journal of Pediatrics 2010, 36:39
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nary enzyme levels, enzymes levels were expressed as
ratio of enzyme activity to urinary creatinine level. Mark-
ers of oxidative stress were assessed by measuring serum
total antioxidant capacity (STAC) (Biodiagnostic, Giza,
Egypt) by specific ELISA kit [14] and urinary malondial-
dehyde (UMDA) by chemical method [15]. The lower
detection limits were 0.31 mg/dL (0.027 mmol/L) for cre-
atinine, 0.2 ng/mL for CysC, 2.0 mg/dL for Ca, 1.0 mg/dL
for PO4, 1.0 mg/dL (0.06 mmol/L) for UA and 0.2 μg/mL
for β2MG.
Data analysis
Statistical Science for Social Package (SPSS Inc, USA)
software computer program version 12 was used for data
analysis. Data were presented as mean ± standard devia-
tion (SD) or number and percentage (n, %) as appropriate.
For comparison of two groups the nonparametric test for
independent variables was used while, comparisons of
multiple groups were done using one-way analysis of
variation (ANOVA) and Kruskall Wallis tests for para-
metric and non-parametric variables, respectively. Spear-
man's and Pearson's correlation tests were used as
appropriate for correlating non-parametric and paramet-
ric variables. For all tests, a probability (P) < 0.05 was con-
sidered significant.
Results
Table 1 showed the demographic characteristics of the
patients and controls. There were no significant differ-
ences regarding gender, age, weight, height and BMI
between patients and controls (P > 0.05 for all). No signif-
icant difference was found between patient's subgroups
regarding disease onset, 1st blood transfusion onset, dis-
ease duration, blood transfusion duration, splenectomy
duration, duration between splenectomy and 1st blood
transfusion, puberty age and family history of thalassemia
(P > 0.05 for all) (Table 2).
In patients with and without chelation therapy, signifi-
cant higher levels of serum levels of CysC (P < 0.0001, P <
0.022), creatinine (P < 0.001, P < 0.008), uric acid (P <
0.0001, P < 0.002), inorganic phosphorus (P < 0.001, P <
0.001), while significant lower levels of TAC (P < 0.0001,
P  < 0.001), eGFRSchwartz  (P  < 0.001, P  < 0.001) were
reported than controls. In patients with chelation ther-
apy, level of SCysC (P < 0.001) was higher while, STAC was
lower (P < 0.048) than patients without chelation therapy.
Impaired renal functions (eGFR < 90 mL/minute/1.73
m2) was reported in 58.82% and 45.71% of patients with
and without chelation (Table 3).
In patient with and without chelation therapy, elevated
urinary levels of NAG/Cr (P < 0.000, P < 0.002), β2MG/Cr
(P < 0.005, P < 0.010), MDA/Cr (P < 0.021, P < 0.045) and
albumin/Cr (P < 0.003, P < 0.006), uric acid (P < 0.008, P <
0.023), calcium (P < 0.003, P < 0.011), inorganic phospho-
rus (P < 0.001, P < 0.006) were reported than those of
controls. Meanwhile, no significant difference was found
in the levels of the urinary measured parameters between
patients with and without chelation therapy. In patients
with and without chelation therapy, normal urinary albu-
min (< 2.5 mg/mmol.Cr) was found in (5.90% and
28.60%%, respectively); microalbuminurea (2.5-30 mg/
mmol.Cr) in (47.10% and 25.70%, respectively) and pro-
teinurea (>30 mg/mmol.Cr) in (47.10% and 45.70%%,
respectively) (Table 4).
In thalassemia patients, SCr showed significant positive
correlation with SUA, SPO4 (r = 0.391, P < 0.010; r = 0.339,
P < 0.010) and negative correlation with SCr (r = -0.309, P
< 0.010). SUA showed significant positive correlation with
Uβ2MG/Cr (r = 0.349, P < 0.010). eGFRSchwartz showed sig-
nificant positive correlation with age, height, weight and
Table 1: The demographic and anthropometric characteristics of blood transfusion-dependant β-thalassemia major 
patients and controls.
Parameters Patients
(n = 69)
Controls
(n = 15)
P-value <
Gender (Male/Female) 45 (65.20%)/24 (34.80%) 11(73.30%)/4 (26.70%) 0.390
Age (years) 8.72 ± 3.70 (1.00-16.00) 8.40 ± 4.10 (3.00-14.00) 0.799
Weight (kg) 22.84 ± 7.04 (8.00-47.00) 23.30 ± 9.38 (11.00-40.00) 0.830
Height (meter) 1.16 ± 0.15 (0.80-1.47) 1.15 ± 0.18 (0.90-1.35) 0.941
Body mass index (kg/m2) 16.59 ± 2.13  (12.5-22.22) 16.80 ± 3.38 (12.19-22.40) 0.759
Data presented are mean +/- SD (range) or number (%); P-value, significance versus controls.Hamed and ElMelegy Italian Journal of Pediatrics 2010, 36:39
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STAC (r = 0.374, P < 0.002; r = 0.319, P < 0.008; r = 0.300, P
< 0.012; r = 0.313, P < 0.009) and negative correlation
with SPO4, SUA, SCysC (r = -0.298, P < 0.013; r = -0.349, P <
0.003; r = -0.517, P < 0.001). SCysC showed significant pos-
itive correlation with SCr (r = 0.659, P < 0.001) and nega-
tive correlation with STAC (r = -0.295, P < 0.014). Ualbumin/
Cr showed significant positive correlation with SUA,
UNAG/Cr, UMDA/Cr, Uβ2MG/Cr (r = 0.339, P < 0.010; r =
0.885, P < 0.001; r = 0.845, P < 0.001; r = 0.991, P < 0.001).
UNAG/Cr showed significant positive correlation with
UMDA/Cr, Uβ2MG/Cr (r = 0.845, P < 0.001; r = 0.900, P <
0.001). UMDA/Cr showed significant positive correlation
with Uβ2MG/Cr and SUA (r = 0.861, P < 0.001; r = 0.251, P <
0.050) (Table 5).
Discussion
Several investigations about renal involvement in adult
βTM patients [4,5,7,16,17] were reported but there is a
dearth of pediatric data. This study aimed to investigate
the presence of glomerular and/or tubular dysfunctions
in children and adolescent with TD- βTM, without any
overt renal diseases, using both conventional and early
markers of glomerular and tubular dysfunctions, and to
correlate the findings to oxidative stress markers and iron
chelation therapy with DFO. Results of this study showed
impaired in classical (Cr, albumin and eGFR) and early
(CysC) glomerular function markers in βTM patients
than controls. Mean serum level of Cr was significantly
higher while eGFR was significantly lower in patients
with and without chelation therapy than controls.
Impaired eGFR (< 90 mL/minute/1.73 m2) was found in
58.82% and 45.71% of patients with and without chelation
therapy. In this respect, Grundy et al. [18] reported high
serum level of Cr in βTM patients. In contrast, Li Volti et
al. [19] and Aldudak et al. [5] found normal SCr, and crea-
tinine clearance (CrC) in patients who received subcuta-
neous DFO treatment. In consistence with others [20], we
Table 2: The clinical characteristics of blood transfusion-dependant-thalassemia major patients.
Parameters All patients Patients subgroups P-value <
(n = 69)
With chelation
[Group I]
(n = 34)
Without chelation
[Group II]
(n = 35)
Disease onset age (months) 13.74 ± -14.55
(2.00-60.00)
12.59 ± 12.77
(2.00-60.00)
14.86 ± 16.21
(2.00-60.00)
0.202
Disease duration (months) 87.42 ± 42.95
(3.00-180.00)
103.21 ± 38.95
(26.00-180.00)
72.09 ± 41.34
(3.00-174.00)
0.991
1st blood transfusion onset (months) 13.74 ± 14.55
(2.00-60.00)
12.59 ± 12.77
(2.00-60.00)
14.86 ± 16.21
(2.00-60.00)
0.202
Blood transfusions/year 9.68 ± 2.96
(6.00-15.00)
9.65 ± 2.79
(6.00-12.00)
9.71 ± 3.16
(6.00-15.00)
0.202
Splenectomy 40 (58.00%) 23 (67.60%) 17 (48.90%) 0.464
Splenectomy duration (months) 37.75 ± 22.43
(3.00-96.00)
42.87 ± 20.76
(12.00-96.00)
30.82 ± 23.35
(3.00-84.00)
0.087
Duration between splenectomy & 1st blood transfusion
(months)
62.10 ± 35.28
(6.00-150.00)
69.48 ± 33.16
(6.00-137.00)
52.12 ± 36.57
(6.00-150.00)
0.520
Puberty age (years) 12.28 ± 0.46
(12.00-13.00)
12.17 ± 0.39
(12.00-13.00)
12.50 ± 0.55
(12.00-13.00)
0.055
Positive family history 13 (18.80%) 9 (26.50%) 4 (11.40%) 0.098
Data presented are mean +/- SD (range) or number (%); P-value, significance between patients with and without chelation therapy.Hamed and ElMelegy Italian Journal of Pediatrics 2010, 36:39
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did not find any variation of serum Cr with age, mean-
while, Helin et al. [21] found a positive correlation
between age and Cr. Stevens and Levey [11] found a posi-
tive correlation between eGFR and age, height, weight
and 1st blood transfusion age in thalassemia patients. In
accordance, microalbuminurea and proteinurea were
reported in our patients with (47.10% and 47.10%) and
without chelation therapy (25.70% and 45.70%). Albu-
minurea found in this study could be attributed mainly to
destruction of glomerular filtration membrane which
proven by decreased in eGFR as well as tubulopathy. In
accordance, Mohkam et al. [22] found proteinuria in
89.3% of βTM patients. Katopodis et al. [23] reported
proteinuria and microalbuminuria in patients with sickle
cell beta-thalassemia and related these finding to pro-
longed glomerular hyperfiltration, glomerulosclerosis,
prostaglandin secretion and chronic anemia.
Table 3: Biochemical parameters in serum of β-thalassemia major patients' groups and controls.
Parameters Controls Patient groups
(n = 15)
With chelation
[Group I]
(n = 34)
Without chelation
[Group II]
(n = 35)
Cystatin-C (mg/L) 0.83 ± 0.05 1.26 ± 0.34 1.03 ± 0.26
Range (0.80 - 0.90) (0.85-2.00) (0.82-2.12)
Significance P < 0.0001 P < 0.022, *P < 0.001
Creatinine (mg/dL) 0.55 ± 0.08 0.75 ± 0.18 0.70 ± 0.21
Range (0.50 -0.70) (0.50-1.10) (0.40-1.10)
Significance P < 0.001 P < 0.008, *P < 0.262
eGFRSchwartz (mL/min/1.73 m2) 119.08 ± 11.13 92.67 ± 25.16 93.73 ± 25.53
Range (96.25-125.40) (53.17-125.40) (49.50-125.40)
Significance P < 0.001 P < 0.001, *P < 0.852
≥90 mL/minute/1.73 m2 15 (100.00%) 14 (41.18%) 19 (54.29%)
< 90 mL/minute/1.73 m2 20 (58.82%) 16 (45.71%)
Uric acid (mg/dL) 3.81 ± 1.19 5.69 ± 1.69 5.30 ± 1.49
Range (2.50-5.50) (2.00-8.50) (2.50-7.50)
Significance P < 0.0001 P < 0.002, *P < 0.292
Calcium (mg/dL) 9.35 ± 1.11 9.10 ± 1.41 8.59 ± 1.86
Range (8.01-10.95) (6.09-11.10) (5.35-12.37)
Significance P < 0.121 P < 0.607, *P < 0.183
Inorganic phosphate (mg/dL) 3.32 ± 0.72 4.69 ± 0.87 4.50 ± 1.14
Range (2.38-4.40) (3.60-7.11) (2.31-6.92)
Significance P < 0.001 P < 0.001, *P < 0.412
Total antioxidant capacity (mmol/L) 0.43 ± 0.12 0.18 ± 0.10 0.23 ± 0.13
Range (0.24-0.60) (0.03-0.36) (0.02-0.41)
Significance P < 0.0001 P < 0.0001, *P < 0.048
Data presented are mean +/- SD (range) or number (%); eGFR, estimated glomerular filtration rate. P-value, significance versus controls; *P-
value, significance versus patients with chelation therapy.Hamed and ElMelegy Italian Journal of Pediatrics 2010, 36:39
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Cystatin-C is a 122-amino acid non-glycosylated low
molecular weight (13 kDa) protein that inhibits cysteine
proteases. It is considered to be a housekeeping gene
since it is transcribed at a relatively constant level and is
expressed in all nucleated cells. CysC is filtered by glom-
eruli and is followed by tubular reabsorption and degra-
dation resulting in excretion of a minute amount in the
urine. It is not secreted by the renal tubules and not reab-
sorbed back into the serum. Therefore, its serum levels
serve as an endogenous parameter of GFR [24-26]. In this
study, SCysC was significantly higher in patients with and
without chelation therapy than controls. Also, SCysC
Table 4: Biochemical parameters in urine of β-thalassemia major patients' groups and controls.
Parameters Controls Patients groups
(n = 15)
With chelation
[Group I]
(n = 34)
Without chelation
[Group II]
(n = 35)
Albumin/Cr (mg/mmol) 1.56 ± 0.51 68.19 ± 79.85 63.35 ± 79.89
Range (0.50-2.00) (1.20-216.00) (0.50-300.00)
Significance P < 0.003 P < 0.006, *P < 0.779
Normal albumin, < 2.5 mg/mmol.creatinine  15 (100.00%) 2 (5.90%) 10 (28.60%)
Microalbuminurea,2.5-30 mg/mmol.creatinine  - 16 (47.10%) 9 (25.70%)
Proteinuria, > 30 mg/mmol.creatinine  - 16 (47.10%) 16 (45.70%)
NAG/Cr (U/mg) 7.47 ± 2.28 15.00 ± 6.17 13.84 ± 7.60
Range (3.00-9.50) (6.00-25.00) (3.00-30.00)
Significance P < 0.000 P < 0.002, *P < 0.453
β2MG/Cr (ug/mg) 11.40 ± 6.70 70.90 ± 71.40 65.40 ± 74.00
Range (1.80-22.00) (3.00-220.00) (0.90-280.00)
Significance P < 0.005 P < 0.010, *P < 0.730
Uric acid (mg/dL) 25.20 ± 5.62 38.97 ± 18.53 36.86 ± 17.05
Range (16.00-32.00) (15.00-70.00) (16.00-70.00)
Significance P < 0.008 P < 0.023, *P < 0.593
Calcium (mg/dL) 9.01 ± 1.20 13.24 ± 4.53 12.63 ± 5.26
Range (7.50-23.00) (7.50-23.00) (7.00-25.00)
Significance P < 0.003 P < 0.011, *P < 0.569
Inorganic phosphorus (mg/dL) 11.83 ± 7.42 48.32 ± 38.83 42.53 ± 38.04
Range (6.00-25.00) (6.00-110.00) (5.00-120.00)
Significance P < 0.001 P < 0.006, *P < 0.495
MDA/Cr (nmol/mg) 13.57 ± 3.69 21.29 ± 9.77 20.20 ± 12.93
Range (2.50-18.00) (10.00-41.00) (4.00-50.00)
Significance P < 0.021 P < 0.045, *P < 0.671
Data presented are mean +/- SD (range) or number (%); Cr, creatinine; NAG, N-acetyl-beta-D-glucosaminidase; β2MG, β2-microglobulin; MDA, 
malondialdehyde; P-value, significance versus controls; *P-value, significance versus patients with chelation therapy.H
a
m
e
d
 
a
n
d
 
E
l
M
e
l
e
g
y
 
I
t
a
l
i
a
n
 
J
o
u
r
n
a
l
 
o
f
 
P
e
d
i
a
t
r
i
c
s
 
2
0
1
0
,
 
3
6
:
3
9
h
t
t
p
:
/
/
w
w
w
.
i
j
p
o
n
l
i
n
e
.
n
e
t
/
c
o
n
t
e
n
t
/
3
6
/
1
/
3
9
P
a
g
e
 
7
 
o
f
 
1
0
Table 5: Correlation coefficient (r) among various parameters in β-thalassaemia major (βTM) pediatric patients.
Parameters Duration 
of 
disease
Age BMI SCysC SCr STAC SUA SCa SPO4 eGFR UNAG/Cr UB2MG/Cr UMDA/Cr
Age 0.941***
BMI 0.387** 0.356**
SCysC 0.168 0.101 0.046
SCr 0.051 -0.078 -0.027 0.659***
STAC 0.161 0.042 0.193 -0.293* -0.309**
SUA 0.073 0.002 -0.091 0.142 0.319** -0.077
SCa -0.101 -0.077 -0.047 0.091 -0.169 0.105 0.078
SPO4 0.054 0.023 0.055 0.150 0.339** 0.212 0.055 -0.325**
eGFR 0.229 0.374** 0.097 -0.517** -0.892*** 0.312** -0.349** 0.144 -0.298*
UNAG/Cr 0.070 0.144 -0.021 0.141 0.159 0.014 0.220 0.020 0.020 -0.083
UB2MG/Cr 0.036 0.117 -0.081 0.094 0.0161 -0.018 0.349** -0.076 0.076 -0.096 0.900***
UMDA/Cr 0.010 0.068 -0.072 0.142 ± 0.188 0.041 0.251* 0.023 0.108 -0.091 0.853*** 0.861***
Ualbumin/Cr 0.089 0.088 -0.105 0.071 0.146 0.024 0.339** -0.084 0.085 -0.088 0.885*** 0.991*** 0.845***
Significance: *: P < 0.05; **: P < 0.01; ***: P < 0.001
BMI, body mass index; SCysC, serum cystatin-C; SCr, serum creatinine, STAC, serum total antioxidant capacity; SUA, serum uric acid; SCa, serum calcium; SPO4, serum inorganic phosphorus; eGFR, estimated 
glomerular filtration rate; UNAG/Cr, urinary N-acetyl-beta-D-glucosaminidase to creatinine; UB2MG/Cr, urinary β2-microglobulin to creatinine; UMDA/Cr, urinary malondialdehyde to creatinine; Ualbumin/Cr, 
urinary albumin to creatinine.Hamed and ElMelegy Italian Journal of Pediatrics 2010, 36:39
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showed significant positive correlation with SCr but nega-
tive correlation with eGFR. In consistence, Voskaridou et
al. [27] reported high SCysC levels in 32.1% of patients with
sickle cell/beta-thalassemia. Economou et al. [28]
reported 36% of their βTM patients had elevated SCysC.
The data compared correlation coefficients between GFR
and reciprocals of serum creatinine and CysC in 3,703
subjects, finding significantly better correlations for CysC
and suggesting that CysC is superior to serum Cr for
detection of impaired GFR in cross-sectional studies [24].
In consistence with others [20], we did not find any corre-
lation of CysC with age, weight, height or gender. In con-
trast, MacDonald et al. [29] reported that SCysC is not
independent of body composition, as previously thought.
These authors showed that past studies were based on the
fact that CysC is produced at a constant rate by all nucle-
ated cells, but 60% of cellular mass comes from muscles,
which varies with anthropometric measures, diet, genet-
ics and physical activity.
The results of the present study also showed signs of
renal tubulopathy, such as increase in serum levels uric
acid and inorganic phosphorus and urinary excretion of
albumin, uric acid, calcium and inorganic phosphorus in
thalassaemic patients with and without chelation therapy
compared to healthy controls. The increased serum and
excretory levels of UA and PO4 can be explained by rapid
erythrocyte turnover in combination with decreased
reabsorption of filtered UA and PO4 from damaged renal
tubules. Similarly, Lapatsanis et al. [30] reported phos-
phaturia and increase in serum phosphorus levels in βTM
patients. In Turkey, Aldudak et al. [5], reported elevated
urinary levels of protein/Cr and serum levels of UA and
PO4 in βTM patients. Mohkam et al. [22] and Economou
et al. [28] reported hypercalciuria in a large number of
thalassemia patients. Smolkin et al. [31] found hyperuri-
cosuria without hyperuricemia and hypercalciuria in
βTM patients without relation to DFO treatment. The
authors attributed hypercalciuria to hypoparathyroidism
and related treatment with calcium and vitamin D [31].
Grundy et al. [18] reported lower serum levels of calcium
and phosphate in children with βTM and contributed
their findings to either liver or parathyroid glands
involvement. In our studied patients, these findings
reflect proximal tubular damage, as none of our patients
suffered from liver diseases or hypoparathyroidism or
received relative supplements.
N-acetyl-beta-D-glucosaminidase (EC 3.2.1.30) is a
high molecular weight (140.000 Dalton) lysozomal
enzyme. It is not specific to the kidney and found in other
tissues as well. It cannot pass into glomerular ultrafilter-
ate due to its high molecular weight. This enzyme shows
high activity in renal proximal tubular cells. As, urinary
NAG is not of plasmatic origin and is not filtered through
the glomeruli, so enhanced UNAG is due to nonspecific
release of tubular proteins as results of tubular dysfunc-
tion and tubular proteinuria and not secondary to loss of
glomerular selectivity [27,32]. β2MG is a low molecular
weight protein (11.8 kDa) which, under normal circum-
stances, is freely filtered at the glomerulus but almost
totally reabsorbed and degraded by renal tubules [33].
Elevation of urinary β2MG is a sensitive and reliable early
marker of tubular dysfunction [34,35]. In our study, the
significant elevated excretion of NAG/Cr and β2MG/Cr
in βTM patients with and without chelation therapy than
those of controls indicate proximal tubular renal damage.
In a similar way, others reported high UNAG activities
[3,4,16,22,27,31] and β2MG excretion [27,28,36] in thalas-
semic patients. In this study, a significant positive correla-
tion was found between UNAG/Cr and Uβ2MG/Cr ratios
and between them and Ualbumin/Cr. In consistence, Moh-
kam et al. [22] found that proteinuria was positively cor-
related with UNAG/Cr ratio. As such, UNAG  can be
considered a sensitive and reliable index of proximal
tubular dysfunctions in βTM patients.
The underlying mechanism for renal dysfunctions in
patients with βTM is not clear. They seem to be multifac-
torial, attributed mainly to include long-standing anemia,
chronic hypoxia, iron overload and deferoxamine toxicity
[5,16,37]. In βTM patients with and without chelation, we
found significant decreased serum levels of TAC (irre-
spective of high serum uric acid in our patients) and
increase urinary excretion of MDA. Also, we found in
thalassemia patients, STAC was significantly positively cor-
related with eGFR, negatively with SCys, SCr and UMDA/Cr
was positive significant correlation with each of UNAG/Cr,
Uβ2MG/Cr and Ualbumin/Cr. This emphasis the role of oxi-
dative stress in inducing renal tubular damage [5,38,39].
Although severe anemia and chronic hypoxia are believed
to play a role in renal involvement in βTM, lipid peroxi-
dation is currently the most favored hypothesis: accord-
ing to this hypothesis, the imbalance in synthesis of
hemoglobin (Hb) leads to excess unpaired globin chain
and high intracellular content of non-Hb iron. The unsta-
ble Hb subunits are known to generate free oxygen radi-
cal species that starting a chain of oxidative events which
leading to disintegration of denatured globin chains,
heme, and iron, which bind to different membrane pro-
teins and altering their normal structure and functions.
In addition, the excess free iron is known to be a catalyst
of lipid peroxidation via the fenton reaction [39].
Although transfusion therapy prolongs survival in
βTM, the absence of a physiological iron excretion mech-
anism leads to uneven accumulation of this metal in vari-
ous body organs results in death, usually during the
second decade of life [40]. Therefore, lifelong chelationHamed and ElMelegy Italian Journal of Pediatrics 2010, 36:39
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therapy, the most common of which is deferoxamine,
which produces iron excretion in urine and stool, is an
essential facet in the management of β-thalassemia
patients [41]. The data obtained from this study showed
decreased in both glomerular and tubular functions in
βTM pediatric patients on a hypertransfusion protocol
with regular DFO chelation therapy program. In addition,
SCysC (indicator of glomerular dysfunction) was signifi-
cantly higher while STAC (indicator of total antioxidant
capacity) was significantly lower in patients on DFO ther-
apy than those without chelation therapy. Meanwhile,
large number of patients on DFO therapy showed
impaired eGFR (58.82%), microalbuminurea (47.10%) and
proteinurea (47.10%) suggesting nephrotoxic effect of
DFO. Although our patients received DFO subcutane-
ously in doses that are considered non-nephrotoxic
according to a generally accepted protocol [42], the possi-
bility that chronic administration of this agent caused
duration dependent kidney damage cannot be excluded.
In consistency, Koren et al. [6] reported that subcutane-
ous administration of DFO was associated with a clini-
cally significant decrease in GFR in 40% of βTM patients
and with a mild decrease in another 40%. Mohkam et al.
[22] found a significant relationship between UNAG and
d u r a t i o n  o f  D F O  t h e r a p y .  O n  c o n t r a ry ,  o t h e r s  [ 4 , 5 , 1 6 -
18,31] reported no detrimental effect of DFO on renal
functions. On contrary, others [4] reported lower level of
UMDA in groups treated with DFO than those without
treatment which supports the hypothesis of direct sup-
pressive effect of DFO on peroxidation.
Conclusions
The presented data confirm that glomerular and tubular
dysfunctions exist in children and adolescent with TD-
βTM. These abnormalities are mainly sub-clinical, but,
with prolonged repeated tubule damage, tubulointersti-
tial fibrosis may occur. As renal dysfunction may not be
detected by routine tests, use of early markers is recom-
mended. CysC is a promising marker of monitoring of
glomerular dysfunction. Urinary NAG excretion can be
considered a reliable index of the tubular toxicity and a
possible predictor of proteinuria. In βTM, the renal dys-
function may be partially explained by excessive oxidative
stress as well as by deferoxamine toxicity. Based on the
results of our study, the usefulness of alternative chelation
drugs and their effects on glomerular and tubular func-
tions should be studied. The administration of selective
antioxidants, along with an appropriate, nutritionally bal-
anced diet would represent a promising approach
towards counteracting oxidative damage and its deleteri-
ous effects on thalassemia.
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